| Outcome Measures: |
Primary: Change in HbA1c, To assess change from baseline in glycated hemoglobin (HbA1c), at 12 weeks after switching to Teneligliptin | Secondary: Change in HbA1c, To assess change from baseline in HbA1c, at 24, 52 weeks after switching to Teneligliptin|Change in FBG, To assess change from baseline in fasting blood glucose (FBG), at 12, 24, 52 weeks after switching to Teneligliptin|Change in body weight, BMI, To assess change from baseline in body weight and body mass index (BMI), at 12, 24, 52 weeks after switching to Teneligliptin|Change in lipid profile(Total cholesterol, LDL cholesterol, HDL cholesterol), To assess change from baseline in serum lipid profile (total cholesterol, LDL and HDL cholesterol, triglyceride), at 12, 24, 52 weeks after switching to Teneligliptin|The percentage of patients with HbA1c <7.0% and <6.5%, To assess the percentage of patients with HbA1c \<7.0% and \<6.5%, at Weeks 12, 24, and 52 of teneligliptin treatment|The percentage of patients with a decrease from baseline in HbA1c, To assess the percentage of patients with a decrease from baseline in HbA1c by ≥0.3% and ≥ 0.5%, at Weeks 12, 24, and 52 of teneligliptin treatment|Safety Outcome, To assess the safety of teneligliptin treatment(AE, ADR, SAE etc.), at Weeks 12, 24, and 52 of teneligliptin treatment
|
